Fed. Circ. Denies Eon's Fee Bid In Skelaxin IP Case
Having last year affirmed the invalidity of two patents for the muscle relaxant Skelaxin that King Pharmaceuticals Inc. asserted against Eon Labs Inc., the Federal Circuit ruled Friday that the case...To view the full article, register now.
Already a subscriber? Click here to view full article